Researcher

Harpreet Kaur

Institute of Himalayan Bioresource Technology

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 7, 2026 · JOURNAL ARTICLE

Reprogramming the Tumor Microenvironment and Cancer Therapy via Nanocatalytic Medicine

Acs Nano Medicine

A narrative review proposing nanocatalytic medicine as a conceptual paradigm for TME modulation in cancer, without original experimental data, clinical trials, or quantitative evidence of efficacy or safety.

Hypothesis-GeneratingAmitabha Acharya Harpreet Kaur Cancer, Hypoxia, and Metabolism

Study details

DesignNarrative review

AUG 9, 2026 · JOURNAL ARTICLE

Whole genome sequencing of unusual Hepatitis C virus subtypes and drug resistance analysis during direct-acting antiviral therapy in India.

Diagnostic Microbiology and Infectious Disease

First descriptive report of HCV genome sequencing and resistance patterns in an Indian cohort; uncontrolled, hospital-based study with small sample and no comparator arm, useful for surveillance but insufficient to guide treatment decisions.

PreliminaryWhole Genome Sequencing Bhupen Barman Onkar Ghuge

Reported

Genotype 3 prevalence64.3% (n=45)

Genotype 6 prevalence21.4% (n=15)

Genotype 1 prevalence14.2% (n=10)